

DAFTAR PUSTAKA

- Alattar, R., Ibrahim, T. B. H., Shaar, S. H., Abdalla, S., Shukri, K., Daghfal, J. N., Khatib, M. Y., Aboukamar, M., Abukhattab, M., Alsoub, H. A., Almaslamani, M. A., & Omrani, A. S. (2020). Tocilizumab for the treatment of severe coronavirus disease 2019. *Journal of Medical Virology*, *92*(10), 2042–2049. <https://doi.org/10.1002/jmv.25964>
- Al-Saadi, M. A. (2019). Vitamin D3 and Liver Protection. In *Dietary Interventions in Liver Disease* (pp. 257–261). Elsevier. <https://doi.org/10.1016/B978-0-12-814466-4.00021-5>
- Angriman, F., Ferreyro, B. L., Burry, L., Fan, E., Ferguson, N. D., Husain, S., Keshavjee, S. H., Lupia, E., Munshi, L., Renzi, S., Ubaldo, O. G. V., Rochweg, B., & Sorbo, L. D. (2021). Interleukin-6 receptor blockade in patients with COVID-19: Placing clinical trials into context. *The Lancet Respiratory Medicine*, *9*(6), 655–664. [https://doi.org/10.1016/S2213-2600\(21\)00139-9](https://doi.org/10.1016/S2213-2600(21)00139-9)
- Bai, S., Jorga, K., Xin, Y., Jin, D., Zheng, Y., Damico-Beyer, L. A., Gupta, M., Tang, M., Allison, D. E., Lu, D., Zhang, Y., Joshi, A., & Dresser, M. J. (2012). A Guide to Rational Dosing of Monoclonal Antibodies. *Clinical Pharmacokinetics*, *51*(2), 119–135. <https://doi.org/10.2165/11596370-000000000-00000>
- Biswas, R. (2020). Are Men More Vulnerable to Covid-19 as Compared to Women? *Biomedical Journal of Scientific & Technical Research*, *27*(2). <https://doi.org/10.26717/BJSTR.2020.27.004481>
- Cascella, M., Rajnik, M., Aleem, A., Dulebohn, S. C., & Di Napoli, R. (2023). Features, Evaluation, and Treatment of Coronavirus (COVID-19). In *StatPearls*. StatPearls Publishing.
- Cindrayani, S., Sukmana, D. J., Hadiatun, N., & Aini, A. (2023). Literature Review: Hubungan dan Peranan Interleukin-6 (Il-6) pada Penderita COVID-19. *JSN : Jurnal Sains Natural*, *1*(3), Article 3. <https://doi.org/10.35746/jsn.v1i3.391>
- Drucker, C., Gewiese, J., Malchow, S., Scheller, J., & Rose-John, S. (2010). Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration. *Journal of Autoimmunity*, *34*(1), 29–37. <https://doi.org/10.1016/j.jaut.2009.08.003>

- Dumanauw, J. M., Barung, E. N., & Korobu, R. I. (2015). *PENGARUH PEMBERIAN SEDUHAN TEH HIJAU DAN TEH HITAM (CAMELIA SINENSIS L.) SEBAGAI HEPATOPROTEKTOR TERHADAP FUNGSI HATI PADA TIKUS PUTIH YANG DIINDUKSI PARASETAMOL*.
- Farihatun, A. (2020). *JURNAL STIKES MUHAMMADIYAH CIAMIS : JURNAL KESEHATAN*. 7.
- Firmansyah, D., & Dede. (2022). Teknik Pengambilan Sampel Umum dalam Metodologi Penelitian: Literature Review. *Jurnal Ilmiah Pendidikan Holistik (JIPH)*, 1(2), Article 2. <https://doi.org/10.55927/jiph.v1i2.937>
- Fitriani, N. I. (2021). TINJAUAN PUSTAKA COVID-19: VIROLOGI, PATOGENESIS, DAN MANIFESTASI KLINIS. *Jurnal Medika Malahayati*, 4(3), 194–201. <https://doi.org/10.33024/jmm.v4i3.3174>
- Frey, N., Grange, S., & Woodworth, T. (2010). Population Pharmacokinetic Analysis of Tocilizumab in Patients With Rheumatoid Arthritis. *The Journal of Clinical Pharmacology*, 50(7), 754–766. <https://doi.org/10.1177/0091270009350623>
- Gao, Q., Yin, X., Tan, B., Wang, J., Chen, J., Zhao, B., Yang, Q., & Li, Z. (2022). Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019. *BMC Infectious Diseases*, 22(1), 929. <https://doi.org/10.1186/s12879-022-07896-0>
- Gebhard, C., Regitz-Zagrosek, V., Neuhauser, H. K., Morgan, R., & Klein, S. L. (2020). Impact of sex and gender on COVID-19 outcomes in Europe. *Biology of Sex Differences*, 11(1), 29. <https://doi.org/10.1186/s13293-020-00304-9>
- Genovese, M. C., Kremer, J. M., Van Vollenhoven, R. F., Alten, R., Scali, J. J., Kelman, A., Dimonaco, S., & Brockwell, L. (2017). Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis. *Arthritis & Rheumatology*, 69(9), 1751–1761. <https://doi.org/10.1002/art.40176>
- Gewiese-Rabsch, J., Drucker, C., Malchow, S., Scheller, J., & Rose-John, S. (2010). Role of IL-6 trans-signaling in CCl4 induced liver damage. *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease*, 1802(11), 1054–1061. <https://doi.org/10.1016/j.bbadis.2010.07.023>
- Gorham, J., Moreau, A., Corazza, F., Peluso, L., Ponthieux, F., Talamonti, M., Izzi, A., Nagant, C., Ndieugnou Djangang, N., Garufi, A., Creteur, J., & Taccone, F. S. (2020). Interleukine-6 in critically ill COVID-19 patients: A retrospective analysis. *PLOS ONE*, 15(12), e0244628. <https://doi.org/10.1371/journal.pone.0244628>

- Goyal, R., Faizy, A. F., Siddiqui, S. S., & Singhai, M. (2012). Evaluation of TNF- α and IL-6 Levels in Obese and Non-obese Diabetics: Pre- and Postinsulin Effects. *North American Journal of Medical Sciences*, 4(4), 180–184. <https://doi.org/10.4103/1947-2714.94944>
- Guaraldi, G., Meschiari, M., Cozzi-Lepri, A., Milic, J., Tonelli, R., Menozzi, M., Franceschini, E., Cuomo, G., Orlando, G., Borghi, V., Santoro, A., Di Gaetano, M., Puzzolante, C., Carli, F., Bedini, A., Corradi, L., Fantini, R., Castaniere, I., Tabbì, L., ... Mussini, C. (2020). Tocilizumab in patients with severe COVID-19: A retrospective cohort study. *The Lancet Rheumatology*, 2(8), e474–e484. [https://doi.org/10.1016/S2665-9913\(20\)30173-9](https://doi.org/10.1016/S2665-9913(20)30173-9)
- Guyton, A. C., & Hall, J. E. (2007). Buku ajar fisiologi kedokteran. EGC.
- Hariyanto, T. I., Hardyson, W., & Kurniawan, A. (2021). Efficacy and Safety of Tocilizumab for Coronavirus Disease 2019 (Covid-19) Patients: A Systematic Review and Meta-analysis. *Drug Research*, 71(05), 265–274. <https://doi.org/10.1055/a-1336-2371>
- Hidayani, W. R. (2020). Faktor Faktor Risiko Yang Berhubungan Dengan COVID 19: Literature Review. *Jurnal Untuk Masyarakat Sehat (JUKMAS)*, 4(2), Article 2. <https://doi.org/10.52643/jukmas.v4i2.1015>
- Hitawala, A., Kumar, S., & Gopalakrishna, K. V. (2020). Early Use of Tocilizumab May Prevent Clinical Deterioration in Select COVID-19 Patients: A Case Series. *Cureus*. <https://doi.org/10.7759/cureus.9187>
- Ho, L.-J., Luo, S.-F., & Lai, J.-H. (2015). Biological effects of interleukin-6: Clinical applications in autoimmune diseases and cancers. *Biochemical Pharmacology*, 97(1), 16–26. <https://doi.org/10.1016/j.bcp.2015.06.009>
- Hochrath, K., Stokes, C. S., Geisel, J., Pollheimer, M. J., Fickert, P., Dooley, S., & Lammert, F. (2014). Vitamin D modulates biliary fibrosis in ABCB4-deficient mice. *Hepatology International*, 8(3), 443–452. <https://doi.org/10.1007/s12072-014-9548-2>
- Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., ... Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet*, 395(10223), 497–506. [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5)
- Jasmine, J., Purwanto, D. S., & Kaligis, S. H. M. (2022). *Peran Interleukin-6 sebagai Faktor Prediktif Derajat Keparahan COVID-19*.

- Kang, S., Narazaki, M., Metwally, H., & Kishimoto, T. (2020). Historical overview of the interleukin-6 family cytokine. *Journal of Experimental Medicine*, 217(5), e20190347. <https://doi.org/10.1084/jem.20190347>
- Kaur, S., Bansal, Y., Kumar, R., & Bansal, G. (2020). A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors. *Bioorganic & Medicinal Chemistry*, 28(5), 115327. <https://doi.org/10.1016/j.bmc.2020.115327>
- Kim, G. W., Lee, N. R., Pi, R. H., Lim, Y. S., Lee, Y. M., Lee, J. M., Jeong, H. S., & Chung, S. H. (2015). IL-6 inhibitors for treatment of rheumatoid arthritis: Past, present, and future. *Archives of Pharmacal Research*, 38(5), 575–584. <https://doi.org/10.1007/s12272-015-0569-8>
- King, A. M. Q. (2012). Ninth report of the International Committee on Taxonomy of Viruses. (*No Title*). <https://cir.nii.ac.jp/crid/1370848662549157251>
- Kotch, C., Barrett, D., & Teachey, D. T. (2019). Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. *Expert Review of Clinical Immunology*, 15(8), 813–822. <https://doi.org/10.1080/1744666X.2019.1629904>
- Kyriazis, M., Mikellides, G., Pantelidakis, H., Polycarpou, M., & Panayiotou, B. (2021). COVID-19 Isolation and Risk of Death in Cyprus Elderly People. *Frontiers in Medicine*, 8, 717692. <https://doi.org/10.3389/fmed.2021.717692>
- Lefkowitz, E. J., Dempsey, D. M., Hendrickson, R. C., Orton, R. J., Siddell, S. G., & Smith, D. B. (2018). Virus taxonomy: The database of the International Committee on Taxonomy of Viruses (ICTV). *Nucleic Acids Research*, 46(D1), D708–D717. <https://doi.org/10.1093/nar/gkx932>
- Leung, E., Crass, R. L., Jorgensen, S. C. J., Raybardhan, S., Langford, B. J., Moore, W. J., & Rhodes, N. J. (2022). Pharmacokinetic/Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19. *Clinical Pharmacokinetics*, 61(2), 155–165. <https://doi.org/10.1007/s40262-021-01092-0>
- Li, C. K., & Xu, X. (2010). Host Immune Responses to SARS Coronavirus in Humans. In S. K. Lal (Ed.), *Molecular Biology of the SARS-Coronavirus* (pp. 259–278). Springer. https://doi.org/10.1007/978-3-642-03683-5_16
- Lomanorek, V. Y., & Assa, Y. A. (2016). GAMBARAN KADAR SERUM SERUM GLUTAMIC OXALOACETIC TRANSAMINASE (SGOT) PADA PEROKOK AKTIF USIA > 40 TAHUN. *Jurnal e-Biomedik*, 4(1). <https://doi.org/10.35790/ebm.4.1.2016.11046>

- Mahmud, M., Safadi, R., & Paz, C. (2011). Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: Two case reports. *International Journal of General Medicine*, 657. <https://doi.org/10.2147/IJGM.S23920>
- Mastra, N., Dewi, I. G. A. T. D. P., & Merta, I. W. (2016). KADAR SERUM GLUTAMATE PIRUVAT TRANSAMINASE PECANDU MINUMAN KERAS DI BANJAR AMBENGAN DESA SAYAN UBUD GIANYAR. *Meditory: The Journal of Medical Laboratory*, 4(2). <https://doi.org/10.33992/m.v4i2.44>
- Montolalu, C., & Langi, Y. (2018). Pengaruh Pelatihan Dasar Komputer dan Teknologi Informasi bagi Guru-Guru dengan Uji-T Berpasangan (Paired Sample T-Test). *D'Cartesian*, 7(1), Article 1. <https://doi.org/10.35799/dc.7.1.2018.20113>
- Mould, D. R., & Green, B. (2010). Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies. *BioDrugs*, 24(1), 23–39. <https://doi.org/10.2165/11530560-000000000-00000>
- Muhammadong, M., & Rahmawati, R. (2022). Analisis Kadar Serum Glutamic Oxaloacetic Transaminase (SGOT) dan Serum Glutmic Pyruvic Transaminase (SGPT) pada Petugas Berisiko Tinggi. *Jurnal Keperawatan Profesional (KEPO)*, 3(2), 131–137. <https://doi.org/10.36590/kepo.v3i2.558>
- Muhović, D., Bojović, J., Bulatović, A., Vukčević, B., Ratković, M., Lazović, R., & Smolović, B. (2020). First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19. *Liver International*, 40(8), 1901–1905. <https://doi.org/10.1111/liv.14516>
- Mulhimah, M., Wijayanti, D. R., & Purnomo, F. O. (2022). CORRELATION OF INTERLEUKIN-6 (IL-6) LEVEL AND NUMBER OF LYMPHOCYTES IN COVID-19 POSITIVE PATIENTS AT PERSAHABATAN HOSPITAL. *Medical Technology and Public Health Journal*, 6(1), 84–92. <https://doi.org/10.33086/mtphj.v6i1.2768>
- Nasution, D. P. (2022). *Gambaran Kadar Enzim Aspartat Aminotransferase (Ast) Dan Enzim Alanin Aminotransferase (Alt) Pada Pasien Penderita Sirosis Hati Di Rumah Sakit Efarina Etaham Berastagi.*
- Nasution, H. F. (2016). INSTRUMEN PENELITIAN DAN URGENSINYA DALAM PENELITIAN KUANTITATIF. *Al-Masharif: Jurnal Ilmu Ekonomi Dan Keislaman*, 4(1), Article 1. <https://doi.org/10.24952/masharif.v4i1.721>
- Nasution, I. A. R., Andrajati, R., Syafhan, N. F., & Imaniar, R. (2023). Pengaruh Faktor Risiko terhadap Kejadian Peningkatan Kadar Enzim Transaminase

pada Pasien Covid-19 dengan Terapi Tocilizumab. *JFIONline* / *Print ISSN 1412-1107* / *e-ISSN 2355-696X*, 15(1), Article 1. <https://doi.org/10.35617/jfionline.v15i1.137>

- Nishimoto, N., Terao, K., Mima, T., Nakahara, H., Takagi, N., & Kakehi, T. (2008). Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. *Blood*, 112(10), 3959–3964. <https://doi.org/10.1182/blood-2008-05-155846>
- Notz, Q., Schmalzing, M., Wedekink, F., Schlesinger, T., Gernert, M., Herrmann, J., Sorger, L., Weismann, D., Schmid, B., Sitter, M., Schlegel, N., Kranke, P., Wischhusen, J., Meybohm, P., & Lotz, C. (2020). Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome—An Observational Pilot Study. *Frontiers in Immunology*, 11, 581338. <https://doi.org/10.3389/fimmu.2020.581338>
- Nuryadi, N., Astuti, D., Utami, S., & M Budiantara, M. B. (2017). Dasar-dasar statistik penelitian.
- Pai, M. P. (2012). Drug Dosing Based on Weight and Body Surface Area: Mathematical Assumptions and Limitations in Obese Adults. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*, 32(9), 856–868. <https://doi.org/10.1002/j.1875-9114.2012.01108.x>
- Papapostoli, I., Lammert, F., & Stokes, C. S. (2016). Effect of Short-Term Vitamin D Correction on Hepatic Steatosis as Quantified by Controlled Attenuation Parameter (CAP). *Journal of Gastrointestinal and Liver Diseases*, 25(2), 175–181. <https://doi.org/10.15403/jgld.2014.1121.252.cap>
- Pilla Reddy, V., El-Khateeb, E., Jo, H., Giovino, N., Lythgoe, E., Sharma, S., Tang, W., Jamei, M., & Rastomi-Hodjegan, A. (2023). Pharmacokinetics under the COVID-19 storm. *British Journal of Clinical Pharmacology*, 89(1), 158–186. <https://doi.org/10.1111/bcp.14668>
- Pratiwi, E. W., & Indarini, E. (2021). Meta Analisis Efektivitas Model Pembelajaran Problem Solving dan Problem Posing Terhadap Kemampuan Berpikir Kritis Matematika Siswa Sekolah Dasar. *Jurnal Basicedu*, 5(2), Article 2. <https://doi.org/10.31004/basicedu.v5i2.854>
- Radbel, J., Narayanan, N., & Bhatt, P. J. (2020). Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome. *Chest*, 158(1), e15–e19. <https://doi.org/10.1016/j.chest.2020.04.024>

- Rauf, A., Abu-Izneid, T., Olatunde, A., Ahmed Khalil, A., Alhumaydhi, F. A., Tufail, T., Shariati, M. A., Rebezov, M., Almarhoon, Z. M., Mabkhot, Y. N., Alsayari, A., & Rengasamy, K. R. R. (2020). COVID-19 Pandemic: Epidemiology, Etiology, Conventional and Non-Conventional Therapies. *International Journal of Environmental Research and Public Health*, 17(21), Article 21. <https://doi.org/10.3390/ijerph17218155>
- Razzaque, M. S., & Taguchi, T. (2003). Pulmonary fibrosis: Cellular and molecular events. *Pathology International*, 53(3), 133–145. <https://doi.org/10.1046/j.1440-1827.2003.01446.x>
- Sagala, S. H., Maifita, Y., & Armaita, A. (2020). HUBUNGAN PENGETAHUAN DAN SIKAP MASYARAKAT TERHADAP COVID-19: A LITERATURE REVIEW. *Menara Medika*, 3(1), Article 1. <https://doi.org/10.31869/mm.v3i1.2197>
- Samaee, H., Mohsenzadegan, M., Ala, S., Maroufi, S. S., & Moradimajd, P. (2020). Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease. *International Immunopharmacology*, 89, 107018. <https://doi.org/10.1016/j.intimp.2020.107018>
- Scott, L. J. (2017). Tocilizumab: A Review in Rheumatoid Arthritis. *Drugs*, 77(17), 1865–1879. <https://doi.org/10.1007/s40265-017-0829-7>
- Sebba, A. (2008). Tocilizumab: The first interleukin-6-receptor inhibitor. *American Journal of Health-System Pharmacy*, 65(15), 1413–1418. <https://doi.org/10.2146/ajhp070449>
- Setiawan, D., Arisandi, D., & Trisnawati, L. (2022). Aplikasi Prediksi Penyakit Sirosis Hati Menggunakan Algoritma Genetika. *Jurnal SANTI - Sistem Informasi dan Teknik Informasi*, 2(1), 31–40. <https://doi.org/10.58794/santi.v2i1.54>
- Sharifi, N., Amani, R., Hajiani, E., & Cheraghian, B. (2014). Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. *Endocrine*, 47(1), 70–80. <https://doi.org/10.1007/s12020-014-0336-5>
- Shi, Y., Wang, G., Cai, X., Deng, J., Zheng, L., Zhu, H., Zheng, M., Yang, B., & Chen, Z. (2020). An overview of COVID-19. *Journal of Zhejiang University. Science. B*, 21(5), 343–360. <https://doi.org/10.1631/jzus.B2000083>
- Sibulesky, L. (2013). Normal liver anatomy. *Clinical Liver Disease*, 2(S1), S1–S3. <https://doi.org/10.1002/cld.124>

- Sidi, M. (2018). *PROGRAM STUDI DIPLOMA III ANALIS KESEHATAN SEKOLAH TINGGI ILMU KESEHATAN INSAN CENDEKIA MEDIKA JOMBANG*.
- Sifareina, S., Alifiar, I., & Priatna, M. (2021). STUDI FARMAKOVIGILANS PADA PASIEN COVID-19. *Pharmacoscrypt*, 4(2), 194–208. <https://doi.org/10.36423/pharmacoscrypt.v4i2.729>
- Sindhu, S., Thomas, R., Shihab, P., Sriraman, D., Behbehani, K., & Ahmad, R. (2015). Obesity Is a Positive Modulator of IL-6R and IL-6 Expression in the Subcutaneous Adipose Tissue: Significance for Metabolic Inflammation. *PLOS ONE*, 10(7), e0133494. <https://doi.org/10.1371/journal.pone.0133494>
- Sivandzadeh, G. R., Askari, H., Safarpour, A. R., Ejtehad, F., Raeis-Abdollahi, E., Vaez Lari, A., Abazari, M. F., Tarkesh, F., & Bagheri Lankarani, K. (2021). COVID-19 infection and liver injury: Clinical features, biomarkers, potential mechanisms, treatment, and management challenges. *World Journal of Clinical Cases*, 9(22), 6178–6200. <https://doi.org/10.12998/wjcc.v9.i22.6178>
- Sodeifian, F., Seyedalhosseini, Z. S., Kian, N., Eftekhari, M., Najari, S., Mirsaedi, M., Farsi, Y., & Nasiri, M. J. (2021). Drug-Induced Liver Injury in COVID-19 Patients: A Systematic Review. *Frontiers in Medicine*, 8, 731436. <https://doi.org/10.3389/fmed.2021.731436>
- Song, S.-N. J., & Yoshizaki, K. (2015). Tocilizumab for treating rheumatoid arthritis: An evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy. *Expert Opinion on Drug Metabolism & Toxicology*, 11(2), 307–316. <https://doi.org/10.1517/17425255.2015.992779>
- Sriyanto, S., Setiawan, L., Fajrunniâ€™mah, R., & Murtiani, F. (2022). Hubungan Kadar Interleukin-6 (IL-6) Dengan Neutrophil Lymphocyte Ratio (NLR) Pada Pasien COVID- 19. *The Indonesian Journal of Infectious Diseases*, 8(1), 10–20. <https://doi.org/10.32667/ijid.v8i1.132>
- Stone, J. H., Tuckwell, K., Dimonaco, S., Klearman, M., Aringer, M., Blockmans, D., Brouwer, E., Cid, M. C., Dasgupta, B., Rech, J., Salvarani, C., Schett, G., Schulze-Koops, H., Spiera, R., Unizony, S. H., & Collinson, N. (2017). Trial of Tocilizumab in Giant-Cell Arteritis. *New England Journal of Medicine*, 377(4), 317–328. <https://doi.org/10.1056/NEJMoa1613849>
- Styawan, D. A. (2021). PANDEMI COVID-19 DALAM PERSPEKTIF DEMOGRAFI. *Seminar Nasional Official Statistics, 2020*(1), 182–189. <https://doi.org/10.34123/semnasoffstat.v2020i1.716>

- Syafitri, S. (2019). PENGARUH PEMBERIAN Curcuma xanthoriza Roxb TERHADAP PERBAIKAN KERUSAKAN SEL HEPAR. *Jurnal Ilmu Kedokteran dan Kesehatan*, 6(3), 236–241. <https://doi.org/10.33024/jikk.v6i3.2192>
- Takaeb, M. J., & Mone, F. (2018). Pengaruh Model Pembelajaran Cooperative Tipe Group Investigation Berbantuan Media Gambar terhadap Prestasi Belajar Siswa Kelas VIII SMP Negeri 3 Soe. *Jurnal Sains Dan Edukasi Sains*, 1(2), Article 2. <https://doi.org/10.24246/juses.v1i2p33-38>
- TIGOCH SANJAYA, 1820011002. (2022). *PENGARUH VARIABEL LINGKUNGAN TERHADAP KEJADIAN COVID-19 DI PROVINSI LAMPUNG* [Masters, UNIVERSITAS LAMPUNG]. <https://digilib.unila.ac.id/63993/>
- Ulfa, R. (2021). Variabel penelitian dalam penelitian pendidikan. *Al-Fathonah*, 1(1), 342-351.
- Vollono, C., Rollo, E., Romozzi, M., Frisullo, G., Servidei, S., Borghetti, A., & Calabresi, P. (2020). Focal status epilepticus as unique clinical feature of COVID-19: A case report. *Seizure*, 78, 109–112. <https://doi.org/10.1016/j.seizure.2020.04.009>
- Widarti, W., & Nurqaidah, N. (2019). ANALISIS KADAR SERUM GLUTAMIC PYRUVIC TRANSAMINASE (SGPT) DAN SERUM GLUTAMIC OXALOACETIC TRANSAMINASE (SGOT) PADA PETANI YANG MENGGUNAKAN PESTISIDA. *Jurnal Media Analis Kesehatan*, 10(1), 35. <https://doi.org/10.32382/mak.v10i1.984>
- Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., Yuan, M.-L., Zhang, Y.-L., Dai, F.-H., Liu, Y., Wang, Q.-M., Zheng, J.-J., Xu, L., Holmes, E. C., & Zhang, Y.-Z. (2020). A new coronavirus associated with human respiratory disease in China. *Nature*, 579(7798), Article 7798. <https://doi.org/10.1038/s41586-020-2008-3>
- Yamaguchi, K., Itoh, Y., Yokomizo, C., Nishimura, T., Niimi, T., Umemura, A., Fujii, H., Okanoue, T., & Yoshikawa, T. (2011). Blockade of IL-6 signaling exacerbates liver injury and suppresses antiapoptotic gene expression in methionine choline-deficient diet-Fed db/db mice. *Laboratory Investigation*, 91(4), Article 4. <https://doi.org/10.1038/labinvest.2011.2>
- Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., Yu, T., Wang, Y., Pan, S., Zou, X., Yuan, S., & Shang, Y. (2020). Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective,

observational study. *The Lancet Respiratory Medicine*, 8(5), 475–481. [https://doi.org/10.1016/S2213-2600\(20\)30079-5](https://doi.org/10.1016/S2213-2600(20)30079-5)

Zhou, J., He, W., Liang, J., Wang, L., Yu, X., Bao, M., & Liu, H. (2021). Association of interleukin-6 levels with morbidity and mortality in patients with coronavirus disease 2019 (COVID-19). *Jpn J Infect Dis*, 74(4), 293-298.

Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., Chen, H.-D., Chen, J., Luo, Y., Guo, H., Jiang, R.-D., Liu, M.-Q., Chen, Y., Shen, X.-R., Wang, X., ... Shi, Z.-L. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*, 579(7798), Article 7798. <https://doi.org/10.1038/s41586-020-2012-7>

Zhou, Z., & Price, C. C. (2020a). Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease. *Expert Opinion on Investigational Drugs*, 29(12), 1407–1412. <https://doi.org/10.1080/13543784.2020.1840549>

Zhou, Z., & Price, C. C. (2020b). Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease. *Expert Opinion on Investigational Drugs*, 29(12), 1407–1412. <https://doi.org/10.1080/13543784.2020.1840549>